[시장보고서]Drug Discovery 아웃소싱 시장 : 규모, 점유율, 동향 분석, 워크플로우별, 의약품별, 서비스별, 치료 영역별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Drug Discovery 아웃소싱 시장 : 규모, 점유율, 동향 분석, 워크플로우별, 의약품별, 서비스별, 치료 영역별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Workflow, By Drug, By Service, By Therapeutics Area, By End Use, By Region, And Segment Forecasts, 2025 - 2033

상품코드 : 1771757

리서치사 : Grand View Research

발행일 : 2025년 06월

페이지 정보 : 영문 120 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,675,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,133,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,049,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

Drug Discovery 아웃소싱 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계 Drug Discovery 아웃소싱 시장 규모는 2033년까지 171억 1,000만 달러에 이르고, 2025년부터 2033년까지의 CAGR은 9.83%를 나타낼 전망입니다. 이를 위해 제약 회사와 생명 공학 회사는 학술 기관 및 비공개 회사(CRO)에 연구 활동을 아웃소싱하기로 선택합니다.

이 시나리오는 코로나 이후에도 계속될 것으로 예측됩니다. 만성 질환 환자 증가로 인해 기업은 수명을 연장하는 의약품의 개발이 강하게 요구되고 있습니다. 기업이 아웃소싱에 적극적으로 참여하는 주요 치료 분야에는 종양학, 심혈관 및 항감염제가 포함됩니다.

COVID-19 팬데믹은 약물 발견과 개발의 가치를 입증했습니다. 전 세계 사람들은 백신을 기다리고 있으며, 여러 기업이 COVID-19와 싸우기 위한 효과적인 백신 개발에 적극적으로 참여하고 있습니다. 화이자(Pfizer Inc.)와 바이오엔텍(BioNTech SE)은 이 바이러스와 싸울 가능성이 있는 균주의 세계의 3상 임상시험 후, 백신의 최초의 승인을 받았습니다. 임상 시험의 경우, 많은 시험이 중단된 반면, 일부는 원격 모니터링 기술을 채택하여 기능하고 있습니다. 이와 같이 팬데믹으로 인해 Drug Discovery 아웃소싱이 바이러스에 대한 효과적인 치료법을 개발하는 중요한 측면이 되어 제약 업계의 중심 무대를 가져 왔습니다.

Drug Discovery 아웃소싱 시장 보고서 및 하이라이트

세계의 Drug Discovery 아웃소싱 시장은 치료 타겟의 복잡화, 연구 개발 비용의 상승, 사내 자원이 한정된 바이오 테크놀로지 기업의 파이프라인 증가 등을 배경으로, 추정 기간 중에 급성장이 전망됩니다.
Drug Discovery 아웃소싱 업계는 프로젝트의 복잡성, 위험 분담 약정, 고객의 요구에 따라 다양한 가격 설정 모델을 이용하고 있습니다.
2024년, 리드화합물의 동정과 후보화합물의 최적화 분야는 워크플로우 분야에 근거한 시장에서 최대의 매출 점유율을 차지했습니다.
약제 유형별로는 2024년의 예측 기간중, 저분자 부문이 최대의 점유율을 차지했습니다.
서비스 부문에 따라 시장은 화학 서비스와 생명 공학 서비스로 구분됩니다.
치료 분야별로는 호흡기계가 2024년 최대 시장 점유율을 차지합니다.
최종 용도별로는 제약 및 바이오테크놀러지 기업이 2024년에 최대 시장 점유율을 차지했습니다.
2024년, 북미는 41.16%의 세계 최대의 매출 점유율을 차지했습니다.

Drug Discovery 아웃소싱 시장(워크플로별) : 부문 대시보드
Drug Discovery 아웃소싱 시장, 워크플로우별 : 변동 분석
워크플로우별, 2021년-2033년
타겟 식별 및 스크리닝
타겟 검증 및 기능 정보 과학
리드 특정 및 후보자 최적화
전임상 개발
기타

제5장 Drug Discovery 아웃소싱 시장 : 의약품 추정 및 예측 분석

Drug Discovery 아웃소싱 시장(의약품별) : 부문 대시보드
Drug Discovery 아웃소싱 시장(의약품별) : 변동 분석
약물별, 2021년-2033년
소분자
거대분자

제6장 Drug Discovery 아웃소싱 시장 : 서비스 추정 및 예측 분석

Drug Discovery 아웃소싱 시장(서비스별) : 부문 대시보드
Drug Discovery 아웃소싱 시장(서비스별) : 변동 분석
서비스별, 2021년-2033년
화학 서비스
생물학 서비스

제7장 Drug Discovery 아웃소싱 시장 : 치료 영역의 추정 및 예측 분석

Drug Discovery 아웃소싱 시장(치료 영역별) : 부문 대시보드
Drug Discovery 아웃소싱 시장(치료 영역별) : 변동 분석
치료 영역별, 2021년-2033년
호흡기계
통증과 마취
종양학
안과
혈액학
심혈관계
내분비
위장
면역조절
항감염성
중추신경계
피부과
비뇨 생식기계

제8장 Drug Discovery 아웃소싱 시장 : 최종 용도의 추정 및 예측 분석

Drug Discovery 아웃소싱 시장(최종 용도별) : 부문 대시보드
Drug Discovery 아웃소싱 시장(최종 용도별) : 변동 분석
용도별, 2021년-2033년
제약 및 바이오테크놀러지 기업
학술기관

제9장 Drug Discovery 아웃소싱 시장 : 지역 추정 및 예측 분석

지역 시장 대시보드
지역별 시장 점유율 분석, 2024년 및 2033년
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 태국
- 한국
- 호주
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제10장 경쟁 구도

시장 진출기업의 분류
기업의 시장 점유율/평가 분석, 2024년
기업 프로파일
- Albany Molecular Research Inc.
- EVOTEC
- Laboratory Corporation of America Holdings
- GenScript
- Charles River Laboratories
- WuXi AppTec
- Thermo Fisher Scientific Inc.
- Dalton Pharma Services
- Oncodesign
- Jubilant Biosys
- DiscoverX Corp.
- QIAGEN
- Eurofins SE
- Syngene International Limited
- Dr. Reddy Laboratories Ltd.
- Pharmaron Beijing Co., Ltd.
- TCG Lifesciences Pvt Ltd.
- Domainex Ltd.

SHW

영문 목차

영문목차

Drug Discovery Outsourcing Market Growth & Trends:

The global drug discovery outsourcing market size is expected to reach USD 17.11 billion by 2033 and is expected to expand at a CAGR of 9.83% from 2025 to 2033, according to a new report by Grand View Research, Inc. The COVID-19 pandemic has brought pharmaceutical companies in limelight. Drug discovery is a costly and lengthy process. This has urged pharmaceutical and biotech companies to opt for outsourcing their research activities to academic and private Contract Research Organizations (CROs). Rising partnerships between public or private entities accelerate drug discovery processes, which, in turn, increase the global demand for outsourcing services for drug discovery.

This scenario is expected to sustain post-Covid implications as well. A rise in cases of chronic diseases has urged companies to develop medicines that extend life expectancy. According to the United Nations, people aged 65 years between 2015 and 2020 are expected to live an additional 17 years. Some of the key therapeutic areas where companies are actively involved in outsourcing include oncology, cardiovascular, and anti-infectives. In November 2020, AstraZeneca collaborated with 9 of the foremost oncology medical centers to expedite research in some of the hardest-to-treat cancers. The company will be funding clinical and non-clinical research proposals from members of this network.

The COVID-19 pandemic has demonstrated the value of drug discovery and development. People across the world are waiting for a vaccine while several companies are proactively involved in developing an effective vaccine to combat COVID-19. Pfizer Inc. and BioNTech SE received first approval for the vaccine following a worldwide Phase 3 trial of a potential strain to combat the virus. As for clinical trials, many of them are halted, while some are functional by adopting remote monitoring technologies. Thus, the pandemic has brought the pharmaceutical industry to center stage with drug discovery outsourcing becoming a key aspect to develop effective treatments against the virus. This is expected to boost the market revenue for the next 2 years i.e. a short-term boom, after which it shall regain its original growth curve.

Drug Discovery Outsourcing Market Report Highlights:

The global market is expected to witness rising growth over the estimated time, fueled by the increasing complexity of therapeutic targets, rising research and development costs, and a growing pipeline of biotech companies with limited internal resources.
The drug discovery outsourcing industry utilizes various pricing models for project complexity, risk-sharing arrangements, and client needs.
In 2024, the lead identification and candidate optimization segment held the largest revenue share in the market based on the workflow segment.
Based on the drug type segment, the small molecules segment accounted for the largest share in 2024 during the forecast period.
Based on service segment, the market is segmented into chemistry services and biology services.
Based on the therapeutics area segment, the respiratory system segment accounted for the largest market share in 2024.
Based on the end use segment, the pharmaceutical & biotechnology companies segment accounted for the largest market share in 2024.
In 2024, North America held the largest revenue share of 41.16% globally.

Chapter 1. Research Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Workflow
- 1.2.2. Drug
- 1.2.3. Service
- 1.2.4. Therapeutics Area
- 1.2.5. End Use
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
1.5. Information Or Data Analysis
- 1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity Flow Analysis
- 1.7.2. Parent Market Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Drug Discovery Outsourcing Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
  - 3.2.1.1. Increasing R&D In the Biopharmaceutical Industry
  - 3.2.1.2. Increasing demand for outsourcing Services in Drug Development
  - 3.2.1.3. Increasing number of partnerships in drug discovery research
  - 3.2.1.4. Technological advancements in drug discovery
  - 3.2.1.5. Rising incidence rate of metabolic, genetic, and other chronic diseases
- 3.2.2. Market Restraint Analysis
  - 3.2.2.1. Presence of open-source software packages for drug discovery
  - 3.2.2.2. High manufacturing costs coupled with a high risk of drug failure
3.3. Pricing Model Analysis
3.4. Technology Landscape
3.5. Market Analysis Tools
- 3.5.1. Porter's Five Forces Analysis
- 3.5.2. PESTEL by SWOT Analysis
- 3.5.3. COVID-19 Impact Analysis

Chapter 4. Drug Discovery Outsourcing Market: Workflow Estimates & Trend Analysis

4.1. Drug Discovery Outsourcing Market, By Workflow: Segment Dashboard
4.2. Drug Discovery Outsourcing Market, By Workflow: Movement Analysis
4.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Workflow, 2021 - 2033 (USD Million)
4.4. Target Identification & Screening
- 4.4.1. Target Identification & Screening Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Target Validation & Functional Informatics
- 4.5.1. Target Validation & Functional Informatics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Lead Identification & Candidate Optimization
- 4.6.1. Lead Identification & Candidate Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Preclinical Development
- 4.7.1. Preclinical Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.8. Others
- 4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Drug Discovery Outsourcing Market: Drug Estimates & Trend Analysis

5.1. Drug Discovery Outsourcing Market, By Drug: Segment Dashboard
5.2. Drug Discovery Outsourcing Market, By Drug: Movement Analysis
5.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Drug, 2021 - 2033 (USD Million)
5.4. Small Molecules
- 5.4.1. Small Molecules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Large Molecules
- 5.5.1. Large Molecules Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Drug Discovery Outsourcing Market: Service Estimates & Trend Analysis

6.1. Drug Discovery Outsourcing Market, By Service: Segment Dashboard
6.2. Drug Discovery Outsourcing Market, By Service: Movement Analysis
6.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
6.4. Chemistry Services
- 6.4.1. Chemistry Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Biology Services
- 6.5.1. Biology Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Drug Discovery Outsourcing Market: Therapeutics Area Estimates & Trend Analysis

7.1. Drug Discovery Outsourcing Market, By Therapeutics Area: Segment Dashboard
7.2. Drug Discovery Outsourcing Market, By Therapeutics Area: Movement Analysis
7.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Therapeutics Area, 2021 - 2033 (USD Million)
7.4. Respiratory system
- 7.4.1. Respiratory System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Pain and Anesthesia
- 7.5.1. Pain and Anesthesia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Oncology
- 7.6.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Ophthalmology
- 7.7.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8. Hematology
- 7.8.1. Hematology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.9. Cardiovascular
- 7.9.1. Cardiovascular Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.10. Endocrine
- 7.10.1. Endocrine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.11. Gastrointestinal
- 7.11.1. Gastrointestinal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.12. Immunomodulation
- 7.12.1. Immunomodulation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.13. Anti-infective
- 7.13.1. Anti-infective Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.14. Central Nervous System
- 7.14.1. Central Nervous System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.15. Dermatology
- 7.15.1. Dermatology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.16. Genitourinary System
- 7.16.1. Genitourinary System Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Drug Discovery Outsourcing Market: End Use Estimates & Trend Analysis

8.1. Drug Discovery Outsourcing Market, By End Use: Segment Dashboard
8.2. Drug Discovery Outsourcing Market, By End Use: Movement Analysis
8.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
8.4. Pharmaceutical & Biotechnology companies
- 8.4.1. Pharmaceutical & Biotechnology companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Academic Institutes
- 8.5.1. Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Drug Discovery Outsourcing Market: Regional Estimates & Trend Analysis

9.1. Regional Market Dashboard
9.2. Regional Market Share Analysis, 2024 & 2033
9.3. North America
- 9.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.3.2. U.S
  - 9.3.2.1. Key Country Dynamics
  - 9.3.2.2. Competitive Scenario
  - 9.3.2.3. Regulatory Framework
  - 9.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.3.3. Canada
  - 9.3.3.1. Key Country Dynamics
  - 9.3.3.2. Competitive Scenario
  - 9.3.3.3. Regulatory Framework
  - 9.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.3.4. Mexico
  - 9.3.4.1. Key Country Dynamics
  - 9.3.4.2. Competitive Scenario
  - 9.3.4.3. Regulatory Framework
  - 9.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.4. Europe
- 9.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.2. UK
  - 9.4.2.1. Key Country Dynamics
  - 9.4.2.2. Competitive Scenario
  - 9.4.2.3. Regulatory Framework
  - 9.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.3. Germany
  - 9.4.3.1. Key Country Dynamics
  - 9.4.3.2. Competitive Scenario
  - 9.4.3.3. Regulatory Framework
  - 9.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.4. France
  - 9.4.4.1. Key Country Dynamics
  - 9.4.4.2. Competitive Scenario
  - 9.4.4.3. Regulatory Framework
  - 9.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.5. Italy
  - 9.4.5.1. Key Country Dynamics
  - 9.4.5.2. Competitive Scenario
  - 9.4.5.3. Regulatory Framework
  - 9.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.6. Spain
  - 9.4.6.1. Key Country Dynamics
  - 9.4.6.2. Competitive Scenario
  - 9.4.6.3. Regulatory Framework
  - 9.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.7. Denmark
  - 9.4.7.1. Key Country Dynamics
  - 9.4.7.2. Competitive Scenario
  - 9.4.7.3. Regulatory Framework
  - 9.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.8. Sweden
  - 9.4.8.1. Key Country Dynamics
  - 9.4.8.2. Competitive Scenario
  - 9.4.8.3. Regulatory Framework
  - 9.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.9. Norway
  - 9.4.9.1. Key Country Dynamics
  - 9.4.9.2. Competitive Scenario
  - 9.4.9.3. Regulatory Framework
  - 9.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5. Asia Pacific
- 9.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.2. Japan
  - 9.5.2.1. Key Country Dynamics
  - 9.5.2.2. Competitive Scenario
  - 9.5.2.3. Regulatory Framework
  - 9.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.3. China
  - 9.5.3.1. Key Country Dynamics
  - 9.5.3.2. Competitive Scenario
  - 9.5.3.3. Regulatory Framework
  - 9.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.4. India
  - 9.5.4.1. Key Country Dynamics
  - 9.5.4.2. Competitive Scenario
  - 9.5.4.3. Regulatory Framework
  - 9.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.5. Thailand
  - 9.5.5.1. Key Country Dynamics
  - 9.5.5.2. Competitive Scenario
  - 9.5.5.3. Regulatory Framework
  - 9.5.5.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.6. South Korea
  - 9.5.6.1. Key Country Dynamics
  - 9.5.6.2. Competitive Scenario
  - 9.5.6.3. Regulatory Framework
  - 9.5.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.7. Australia
  - 9.5.7.1. Key Country Dynamics
  - 9.5.7.2. Competitive Scenario
  - 9.5.7.3. Regulatory Framework
  - 9.5.7.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.6. Latin America
- 9.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6.2. Brazil
  - 9.6.2.1. Key Country Dynamics
  - 9.6.2.2. Competitive Scenario
  - 9.6.2.3. Regulatory Framework
  - 9.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6.3. Argentina
  - 9.6.3.1. Key Country Dynamics
  - 9.6.3.2. Competitive Scenario
  - 9.6.3.3. Regulatory Framework
  - 9.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.7. MEA
- 9.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.7.2. South Africa
  - 9.7.2.1. Key Country Dynamics
  - 9.7.2.2. Competitive Scenario
  - 9.7.2.3. Regulatory Framework
  - 9.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.7.3. Saudi Arabia
  - 9.7.3.1. Key Country Dynamics
  - 9.7.3.2. Competitive Scenario
  - 9.7.3.3. Regulatory Framework
  - 9.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.7.4. UAE
  - 9.7.4.1. Key Country Dynamics
  - 9.7.4.2. Competitive Scenario
  - 9.7.4.3. Regulatory Framework
  - 9.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.7.5. Kuwait
  - 9.7.5.1. Key Country Dynamics
  - 9.7.5.2. Competitive Scenario
  - 9.7.5.3. Regulatory Framework
  - 9.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

10.1. Market Participant Categorization
10.2. Company Market Share/Assessment Analysis, 2024
10.3. Company Profiles
- 10.3.1. Albany Molecular Research Inc.
  - 10.3.1.1. Company Overview
  - 10.3.1.2. Financial Performance
  - 10.3.1.3. Service Benchmarking
  - 10.3.1.4. Strategic Initiatives
- 10.3.2. EVOTEC
  - 10.3.2.1. Company Overview
  - 10.3.2.2. Financial Performance
  - 10.3.2.3. Service Benchmarking
  - 10.3.2.4. Strategic Initiatives
- 10.3.3. Laboratory Corporation of America Holdings
  - 10.3.3.1. Company Overview
  - 10.3.3.2. Financial Performance
  - 10.3.3.3. Service Benchmarking
  - 10.3.3.4. Strategic Initiatives
- 10.3.4. GenScript
  - 10.3.4.1. Company Overview
  - 10.3.4.2. Financial Performance
  - 10.3.4.3. Service Benchmarking
  - 10.3.4.4. Strategic Initiatives
- 10.3.5. Charles River Laboratories
  - 10.3.5.1. Company Overview
  - 10.3.5.2. Financial Performance
  - 10.3.5.3. Service Benchmarking
  - 10.3.5.4. Strategic Initiatives
- 10.3.6. WuXi AppTec
  - 10.3.6.1. Company Overview
  - 10.3.6.2. Financial Performance
  - 10.3.6.3. Service Benchmarking
  - 10.3.6.4. Strategic Initiatives
- 10.3.7. Thermo Fisher Scientific Inc.
  - 10.3.7.1. Company Overview
  - 10.3.7.2. Financial Performance
  - 10.3.7.3. Service Benchmarking
  - 10.3.7.4. Strategic Initiatives
- 10.3.8. Dalton Pharma Services
  - 10.3.8.1. Company Overview
  - 10.3.8.2. Financial Performance
  - 10.3.8.3. Service Benchmarking
  - 10.3.8.4. Strategic Initiatives
- 10.3.9. Oncodesign
  - 10.3.9.1. Company Overview
  - 10.3.9.2. Financial Performance
  - 10.3.9.3. Service Benchmarking
  - 10.3.9.4. Strategic Initiatives
- 10.3.10. Jubilant Biosys
  - 10.3.10.1. Company Overview
  - 10.3.10.2. Financial Performance
  - 10.3.10.3. Service Benchmarking
  - 10.3.10.4. Strategic Initiatives
- 10.3.11. DiscoverX Corp.
  - 10.3.11.1. Company Overview
  - 10.3.11.2. Financial Performance
  - 10.3.11.3. Service Benchmarking
  - 10.3.11.4. Strategic Initiatives
- 10.3.12. QIAGEN
  - 10.3.12.1. Company Overview
  - 10.3.12.2. Financial Performance
  - 10.3.12.3. Service Benchmarking
  - 10.3.12.4. Strategic Initiatives
- 10.3.13. Eurofins SE
  - 10.3.13.1. Company Overview
  - 10.3.13.2. Financial Performance
  - 10.3.13.3. Service Benchmarking
  - 10.3.13.4. Strategic Initiatives
- 10.3.14. Syngene International Limited
  - 10.3.14.1. Company Overview
  - 10.3.14.2. Financial Performance
  - 10.3.14.3. Service Benchmarking
  - 10.3.14.4. Strategic Initiatives
- 10.3.15. Dr. Reddy Laboratories Ltd.
  - 10.3.15.1. Company Overview
  - 10.3.15.2. Financial Performance
  - 10.3.15.3. Service Benchmarking
  - 10.3.15.4. Strategic Initiatives
- 10.3.16. Pharmaron Beijing Co., Ltd.
  - 10.3.16.1. Company Overview
  - 10.3.16.2. Financial Performance
  - 10.3.16.3. Service Benchmarking
  - 10.3.16.4. Strategic Initiatives
- 10.3.17. TCG Lifesciences Pvt Ltd.
  - 10.3.17.1. Company Overview
  - 10.3.17.2. Financial Performance
  - 10.3.17.3. Service Benchmarking
  - 10.3.17.4. Strategic Initiatives
- 10.3.18. Domainex Ltd.
  - 10.3.18.1. Company Overview
  - 10.3.18.2. Financial Performance
  - 10.3.18.3. Service Benchmarking
  - 10.3.18.4. Strategic Initiatives